Drawing for Serial No. 79069161

USPTO serial 79069161

Serial No. 79069161

Reviewed by CopyMark Law Group

Reg. 3771814Status 404
Filing date
Status date
Registration date
Apr 6, 2010
Examiner
MARTIN, JENNIFER MCGARRY
Law office
MADRID PROCESSING UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79069161?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

William J. Seiter

WILLIAM J. SEITER Seiter Legal Studio2500 Broadway, Bldg F, Suite F-125Santa Monica, CA 90404UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular system diseases, namely, hypertension, and heart failure; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of nutrition metabolism barrier diseases, namely, malnutrition and beriberi; Pharmaceutical preparations for the treatment of metabolism diseases, namely, diabetes, obesity, diabetic ketoacidosis, hypoxemia DKA and high fat proteinemia; Pharmaceutical preparations for the treatment of endocrine system diseases, namely, next cerebral ganglion pituitary gland sickness, thyroid gland sickness, ophoropathy and parathyroid sickness; Pharmaceutical preparations for the treatment of circulatory system diseases, namely, shock, heart valve sickness, arrhythmia, arteriosclerosis, cardiomyopathy periphery blood vessel disease, hypertensive disease and pericarditis; Pharmaceutical preparations for the treatment of respiratory disorder, namely, chronic bronchitis, bronchial asthma, disease of pulmonary circulation, pneumonia and acute trachea bronchitis; Pharmaceutical preparations for the treatment of digesting system diseases, namely, abdominal pain, constipation, diarrhea, cholecystitus, liver cirrhosis, liver function failure and gastritis; Pharmaceutical preparations for the treatment of urinary system diseases, namely, kidney stone, renal tumor, chronic kidney function failure, urinary tract infection and cystonephrosis; Pharmaceutical preparations for the treatment of hematopoietic system diseases, namely, anemia, leukemia and lymphoma; Pharmaceutical preparations for the treatment of immune system diseases, namely, serum sickness, allergic shock and allergic rhinitis; Pharmaceutical preparations for the treatment of rheumatic diseases and osteoarthritis, namely, rheumatic fever, lupus erythematosus, sjogren's syndrome, behcet disease and dermatomyositis; Pharmaceutical preparations for the treatment of nerve diseases, namely, schizophrenia and neurosis; Pharmaceutical preparations for the treatment of nervous system diseases, namely, headache, multiple sclerosis and muscle diseases; Pharmaceutical preparations for the treatment of skin diseases, namely, eczema, belt-shaped blister measles, namely, herpes zoster, connective tissue disease, lupus erythematosus and nervous dermatitis; Pharmaceutical preparations for the treatment of reproductive system inflammation, namely, pelvic inflammatory disease, cervicitis and vestibule big gland inflammation; Pharmaceutical preparations for the treatment of natural dissemination diseases, namely, gonorrhea, syphilis and AIDS; Pharmaceutical preparations for the treatment of female reproductive system tumor, namely, sarcoma uteri, carcinoma of cervix and endometrium cancer; Pharmaceutical preparations for the treatment of menopathy, namely, menopause, painful menstruation and menopause syndrome; Pharmaceutical preparations for the treatment of newborn symptom and diseases, namely, the newborn faints from fright, newborn vomit and newborn septicaemia; Pharmaceutical preparations for the treatment of surgical department conditions, namely, tetanus, wounds and tumorsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 31, 2018DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Aug 31, 2018DETHDEATH OF INTERNATIONAL REGISTRATION—
Jan 11, 2018ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 4, 2017INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jul 13, 2017XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jul 13, 2017XXCRGENERIC MADRID TRANSACTION CREATED—
Jul 11, 2017INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Nov 11, 2016C71TCANCELLED SECTION 71—
Mar 25, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 7, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 28, 2010FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 28, 2010FIMPFINAL DISPOSITION PROCESSED—
Jul 7, 2010FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 6, 2010R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 19, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 19, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 14, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 8, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 8, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Dec 8, 2009GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 8, 2009GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 8, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 20, 2009CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Nov 18, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 18, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 18, 2009ALIEASSIGNED TO LIE—
Nov 5, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 5, 2009ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 5, 2009REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 24, 2009RFNTREFUSAL PROCESSED BY IB—
Jun 30, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 30, 2009RFRRREFUSAL PROCESSED BY MPU—
Jun 30, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 30, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 29, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2009DOCKASSIGNED TO EXAMINER—
Jun 26, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 25, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance